UBS Initiates Coverage On Nektar Therapeutics with Neutral Rating, Announces Price Target of $53
UBS analyst Alice Nettleton initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Neutral rating and announces Price Target of $53.
Stocks · News reference
8-K filing — NEKTAR THERAPEUTICS (NKTR)
Filed: 2026-10-01 AccNo: 0001213900-26-105453 Size: 24 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Leerink Partners Initiates Coverage On Nektar Therapeutics with Outperform Rating, Announces Price Target of $130
Leerink Partners analyst Will Soghikian initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Outperform rating and announces Price Target of $130.
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target
Raymond James Initiates Coverage On Nektar Therapeutics with Market Perform Rating